68,871 XNAS Volume
XNAS 24 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Matthew Pulisic | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2025 | 275,000 | 275,000 | - | - | Stock Option (right to buy) | |
| L. Tyree James | Director | Sale of securities on an exchange or to another person at price $ 2.46 per share. | 30 Dec 2024 | 3,460 | 45,791 | - | 2.5 | 8,512 | Common Stock |
| Yu Tony | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 39,000 | 39,000 | - | - | Stock Option (right to buy) | |
| Ralph Smalling | Head of Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 21,100 | 21,100 | - | - | Stock Option (right to buy) | |
| Sean Ryder | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Thomas Zindrick | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 183,000 | 183,000 | - | - | Stock Option (right to buy) | |
| Tony Yu | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 29,000 | 39,869 | - | 0 | Common Stock | |
| Sean Ryder | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 22,000 | 41,388 | - | 0 | Common Stock | |
| Zindrick Thomas | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 134,500 | 171,872 | - | 0 | Common Stock | |
| S. Zak Lourie | Chief Financial Officer | 18 Dec 2024 | 56,525 | 56,525 | - | - | Stock Option (right to buy) | ||
| Cappello Joseph | VP, Pharmaceutical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 39,000 | 39,000 | - | - | Stock Option (right to buy) | |
| Joseph Cappello | VP, Pharmaceutical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 29,000 | 43,653 | - | 0 | Common Stock | |
| Zak Lourie S. | Chief Financial Officer | 18 Dec 2024 | 41,650 | 82,452 | - | 0 | Common Stock | ||
| Smalling Ralph | Head of Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Dec 2024 | 15,525 | 31,847 | - | 0 | Common Stock | |
| Ralph Smalling | Head of Regulatory | Sale of securities on an exchange or to another person at price $ 2.34 per share. | 16 Dec 2024 | 2,510 | 16,322 | - | 2.3 | 5,873 | Common Stock |
| Cappello Joseph | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 2.34 per share. | 16 Dec 2024 | 6,300 | 14,653 | - | 2.3 | 14,742 | Common Stock |
| Thomas Zindrick | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.34 per share. | 16 Dec 2024 | 14,315 | 37,372 | - | 2.3 | 33,497 | Common Stock |
| Zak Lourie S. | Chief Financial Officer | 16 Dec 2024 | 2,103 | 40,802 | - | 2.3 | 4,921 | Common Stock | |
| Paul Scigalla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2024 | 16,666 | 16,666 | - | - | Stock Option (right to buy) | |
| Paul Scigalla | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Oct 2024 | 16,666 | 16,666 | - | - | Stock Option (right to buy) | |
| James L. Tyree | Director | Sale of securities on an exchange or to another person at price $ 2.60 per share. | 11 Sep 2024 | 1,730 | 47,521 | - | 2.6 | 4,499 | Common Stock |
| John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| Mary Mirabelli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 39,541 | 52,001 | - | 0 | Common Stock | |
| James L. Tyree | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 39,541 | 49,251 | - | 0 | Common Stock | |
| John W. Smither | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 39,541 | 52,711 | - | 0 | Common Stock | |
| Mary Mirabelli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| James L. Tyree | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| John Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| John Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| James L. Tyree | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| Mirabelli Mary | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| Smither John W. | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 50,469 | 50,469 | - | - | Stock Option Right to Buy) | |
| John Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Aug 2024 | 39,541 | 505,501 | - | 0 | Common Stock | |
| Mary Mirabelli | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 8,000 | 12,460 | - | - | Common Stock | |
| Lourie S. Zak | Chief Financial Officer | 29 May 2024 | 31,250 | 31,250 | - | - | Common Stock Warrant (Right to Buy) | ||
| Lourie S. Zak | Chief Financial Officer | 29 May 2024 | 31,250 | 31,250 | - | - | Common Stock | ||
| Ralph Smalling | Head of Regulatory | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 1,250 | 13,315 | - | - | Common Stock | |
| Ralph Smalling | Head of Regulatory | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 1,250 | 1,250 | - | - | Common Stock Warrant (Right to Buy) | |
| John Thomas | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 2,500 | 2,500 | - | - | Common Stock Warrant (Right to Buy) | |
| John Thomas | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 2,500 | 465,960 | - | - | Common Stock | |
| Mary Mirabelli | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 8,000 | 8,000 | - | - | Common Stock Warrant (Right to Buy) | |
| Sean Ryder | General Counsel | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 10,000 | 10,572 | - | - | Common Stock | |
| James L. Tyree | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 6,250 | 6,250 | - | - | Common Stock Warrant (Right to Buy) | |
| James L. Tyree | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 6,250 | 9,710 | - | - | Common Stock | |
| John W. Smither | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 6,250 | 13,170 | - | - | Common Stock | |
| John W. Smither | Director | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 6,250 | 6,250 | - | - | Common Stock Warrant (Right to Buy) | |
| Thomas Zindrick | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 200,000 | 200,000 | - | - | Common Stock | |
| Thomas Zindrick | Director, President and CEO | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 200,000 | 200,000 | - | - | Common Stock Warrant (Right to Buy) | |
| Tony Yu | VP, Clinical Trial Operations | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 2,500 | 2,500 | - | - | Common Stock Warrant (Right to Buy) | |
| Tony Yu | VP, Clinical Trial Operations | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 2,500 | 2,500 | - | - | Common Stock | |
| Sean Ryder | General Counsel | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 29 May 2024 | 10,000 | 10,000 | - | - | Common Stock Warrant (Right to Buy) | |
| Thomas Zindrick | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 26,264 | 50,207 | - | 0 | Common Stock | |
| Lourie S. Zak | Chief Financial Officer | 19 Feb 2024 | 1,220 | 32,470 | - | 0 | Common Stock | ||
| Lourie S. Zak | Chief Financial Officer | 19 Feb 2024 | 3,852 | 38,428 | - | 0 | Common Stock | ||
| Ralph Smalling | Head of Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 616 | 13,931 | - | 0 | Common Stock | |
| Ralph Smalling | Head of Regulatory | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 2,107 | 18,144 | - | 0 | Common Stock | |
| Caroline Jewett | Head of Quality | Sale of securities on an exchange or to another person at price $ 2.12 per share. | 19 Feb 2024 | 4,961 | 16,174 | - | 2.1 | 10,517 | Common Stock |
| Caroline Jewett | Head of Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 3,612 | 25,890 | - | 0 | Common Stock | |
| Caroline Jewett | Head of Quality | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 1,143 | 22,278 | - | 0 | Common Stock | |
| Sean Ryder | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 2,936 | 13,508 | - | 0 | Common Stock | |
| Sean Ryder | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 9,270 | 22,778 | - | 0 | Common Stock | |
| Joseph Cappello | VP, Pharmaceutical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 3,661 | 9,396 | - | 0 | Common Stock | |
| Joseph Cappello | VP, Pharmaceutical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 11,557 | 20,953 | - | 0 | Common Stock | |
| Tony Yu | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 11,557 | 17,718 | - | 0 | Common Stock | |
| Tony Yu | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 2.12 per share. | 19 Feb 2024 | 6,849 | 10,869 | - | 2.1 | 14,520 | Common Stock |
| Tony Yu | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 3,661 | 6,161 | - | 0 | Common Stock | |
| Thomas Zindrick | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Feb 2024 | 8,320 | 22,971 | - | 0 | Common Stock | |
| Sean Ryder | General Counsel | Sale of securities on an exchange or to another person at price $ 2.12 per share. | 19 Feb 2024 | 5,496 | 19,388 | - | 2.1 | 11,652 | Common Stock |
| Tony Yu | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 12.94 per share. | 15 Dec 2023 | 26,732 | 5,803 | - | 12.9 | 345,915 | Common Stock |
| Yu Tony | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 14.18 per share. | 15 Dec 2023 | 5,803 | 0 | - | 14.2 | 82,265 | Common Stock |
| Thomas John | Director | Sale of securities on an exchange or to another person at price $ 13.23 per share. | 13 Dec 2023 | 7,073 | 465,387 | - | 13.2 | 93,548 | Common Stock |
| Thomas John | Director | Sale of securities on an exchange or to another person at price $ 13.93 per share. | 13 Dec 2023 | 1,927 | 463,460 | - | 13.9 | 26,839 | Common Stock |
| Yu Tony | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 11.85 per share. | 07 Dec 2023 | 36,800 | 32,535 | - | 11.8 | 435,995 | Common Stock |
| Tony Yu | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 24.70 per share. | 30 Aug 2023 | 19,800 | 135,935 | - | 24.7 | 489,060 | Common Stock |
| Thomas Zindrick | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 23.73 per share. | 18 Aug 2023 | 8,349 | 14,651 | - | 23.7 | 198,122 | Common Stock |
| Tony Yu | VP, Clinical Trial Operations | Sale of securities on an exchange or to another person at price $ 23.73 per share. | 18 Aug 2023 | 3,265 | 155,735 | - | 23.7 | 77,478 | Common Stock |
| Joseph Cappello | VP, Pharmaceutical Development | Sale of securities on an exchange or to another person at price $ 23.73 per share. | 18 Aug 2023 | 3,265 | 5,735 | - | 23.7 | 77,478 | Common Stock |
| Doug Samuelson | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 23.73 per share. | 18 Aug 2023 | 1,297 | 2,303 | - | 23.7 | 30,778 | Common Stock |
| Sean Ryder | General Counsel | Sale of securities on an exchange or to another person at price $ 23.73 per share. | 18 Aug 2023 | 328 | 572 | - | 23.7 | 7,783 | Common Stock |
| Caroline Jewett | Head of Quality | Sale of securities on an exchange or to another person at price $ 23.73 per share. | 18 Aug 2023 | 515 | 1,135 | - | 23.7 | 12,221 | Common Stock |
| Ralph Smalling | Head of Regulatory | Sale of securities on an exchange or to another person at price $ 23.73 per share. | 18 Aug 2023 | 935 | 2,065 | - | 23.7 | 22,188 | Common Stock |
| Thomas Zindrick | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 27 Feb 2023 | 23,000 | 23,000 | - | 0 | Common Stock | |
| Qian Zhang | Associate VP, Research | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 6,000 | 139,333 | - | 0 | Common Stock | |
| Gabe Woodward | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 1,000 | 4,186 | - | 0 | Common Stock | |
| John Thomas | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 9,000 | 479,000 | - | 0 | Common Stock | |
| Mary Mirabelli | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 1,000 | 1,000 | - | 0 | Common Stock | |
| Sean Ryder | General Counsel | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 900 | 900 | - | 0 | Common Stock | |
| Doug Samuelson | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 3,600 | 3,600 | - | 0 | Common Stock | |
| Joseph Cappello | VP, Pharmaceutical Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 9,000 | 9,000 | - | 0 | Common Stock | |
| Tony Yu | VP, Clinical Trial Operations | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 9,000 | 159,000 | - | 0 | Common Stock | |
| James L. Tyree | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Feb 2023 | 9,000 | 9,000 | - | 0 | Common Stock | |
| John Thomas | Director | 30 Jan 2023 | 470,000 | 470,000 | - | - | Common Stock | ||
| Gabe Woodward | Director | 30 Jan 2023 | 13,000 | 0 | - | - | Series I Preferred Stock | ||
| Gabe Woodward | Director | 30 Jan 2023 | 7,000 | 0 | - | - | Series J Preferred Stock | ||
| Gabe Woodward | Director | 30 Jan 2023 | 6,000 | 0 | - | - | Series K Preferred Stock | ||
| Gabe Woodward | Director | 30 Jan 2023 | 5,378 | 5,378 | - | - | Common Stock | ||
| Gabe Woodward | Director | 30 Jan 2023 | 2,798 | 2,798 | - | - | Common Stock | ||
| Gabe Woodward | Director | 30 Jan 2023 | 3,186 | 3,186 | - | - | Common Stock | ||
| John Thomas | Director | 30 Jan 2023 | 1,410,000 | 0 | - | - | Series A Preferred Stock | ||
| Qian Zhang | Associate VP, Research | Purchase of securities on an exchange or from another person at price $ 6.25 per share. | 26 Jan 2023 | 200 | 200 | - | 6.3 | 1,250 | Common Stock |